Illumina has acquired Conexio Genomics, based in Fremantle, Western Australia. The acquisition enables Illumina to develop NGS-based transplant diagnostics assays, including a new solution for interrogating genomic variants in the gamma genomic block of the major histocompatibility complex.
Illumina’s partnership with Conexio started in early 2015 with the launch of the TruSight HLA Solution, for which Conexio’s Assign software provides analysis and reporting.
Illumina, 858-202-4500